Madrigal (MDGL) | Stock Overview & Key Data
Madrigal Performance Comparison
Stock Range
Today's Range
Low: $404.16
High: $419.99
on August 22, 2025
52 Week Range
Low: $200.63
High: $419.99
on October 23, 2024
on August 22, 2025
All-Time High: $419.99 on August 22, 2025
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$9.1B
EPS
-12.66
P/E Ratio (TTM)
-18.94
Forward P/E
-29.16
P/B Ratio
13.00
PEG Ratio
0.26
Div. Yield
N/A
ROE
-36.30%
Beta
-1.026
Debt to Equity
17.81
Financial Highlights
Profitability
Gross Margin
95.74%
Operating Margin
-22.18%
Profit Margin
-54.68%
Returns and Earnings
Return on Assets (TTM)
-18.31%
Return on Equity (TTM)
-36.30%
EBITDA
$-308.4M
Net Income (TTM)
$-281.9M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$23.43
Quarterly Revenue Growth (YoY)
1,353.80%
Quarterly Earnings Growth (YoY)
1,353.76%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Madrigal MDGL | 9.07B Mid-cap | 12.12% | 32.32% | 51.70% | 28.73% | 32.16% | 64.07% | 491.89% | 288.86% |
| Vertex VRTX | 100.19B Large-cap | 0.62% | -15.94% | -8.94% | -17.95% | -2.60% | -17.90% | 40.27% | 46.36% |
| Regeneron REGN | 63.57B Large-cap | 1.56% | 5.09% | -1.23% | -17.35% | -17.58% | -50.84% | -1.12% | -2.18% |
| BridgeBio Pharma BBIO | 9.58B Mid-cap | -4.36% | 7.23% | 48.86% | 35.39% | 74.04% | 93.99% | 368.51% | 65.93% |
| Blueprint Medicines BPMC | 8.37B Mid-cap | 0.12% | 1.05% | 53.79% | 15.63% | 48.46% | 12.60% | 149.54% | 73.38% |
| Halozyme HALO | 8.38B Mid-cap | 6.76% | 24.82% | 33.62% | 22.77% | 49.59% | 14.51% | 78.26% | 152.53% |
Ownership & Short Interest
Insider Ownership
7.71%
Institutional Ownership
107.15%
Shares Short
4M
Short Ratio
11.26
Short % of Shares Outstanding
20.76%
Average 10-Day Volume
470K
Average 90-Day Volume
451K
Madrigal Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Madrigal would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is MDGL's 52-week high and low?
- In the last 52 weeks, Madrigal reached a high of $419.99 (on August 22, 2025) and a low of $200.63 (on October 23, 2024).
- What is the market cap and P/E ratio for MDGL?
- Curious about Madrigal's size and valuation? Its market capitalization stands at 9.07B. When it comes to valuation, the P/E ratio (trailing twelve months) is -18.94, and the forward P/E (looking ahead) is -29.16.
- Does MDGL pay dividends? If so, what's the yield?
- As for dividends, Madrigal isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Madrigal's main competitors or similar companies to consider before investing?
When looking at Madrigal, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX100.19B Healthcare Biotechnology -17.90% 40.27% Regeneron
REGN63.57B Healthcare Biotechnology -50.84% -1.12% BridgeBio Pharma
BBIO9.58B Healthcare Biotechnology 93.99% 368.51% Blueprint Medicines
BPMC8.37B Healthcare Biotechnology 12.60% 149.54% Halozyme
HALO8.38B Healthcare Biotechnology 14.51% 78.26% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Madrigal Pharmaceuticals Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Madrigal's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -36.30%, the Debt to Equity ratio from the most recent quarter is 17.81, and its Gross Profit Margin stands at 95.74%.
- What is the recent revenue and earnings growth for MDGL?
- Looking at Madrigal's growth, its revenue over the trailing twelve months (TTM) was $516M. Compared to the same quarter last year (YoY), quarterly revenue grew by 1,353.80%, and quarterly earnings saw a YoY growth of 1,353.76%.
- How much of MDGL stock is held by insiders and institutions?
- Wondering who owns Madrigal stock? Company insiders (like executives and directors) hold about 7.71% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 107.15%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.